Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Diluted Average): 2016-2025

Historic Shares Outstanding (Diluted Average) for Corcept Therapeutics (CORT) over the last 8 years, with Sep 2025 value amounting to $120.0 million.

  • Corcept Therapeutics' Shares Outstanding (Diluted Average) rose 5.50% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.0 million, marking a year-over-year increase of 5.50%. This contributed to the annual value of $113.5 million for FY2024, which is 1.56% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Shares Outstanding (Diluted Average) of $120.0 million as of Q3 2025, which was down 0.42% from $120.5 million recorded in Q2 2025.
  • Corcept Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $129.7 million during Q1 2021, with a 5-year trough of $109.9 million in Q1 2024.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $114.6 million, with a median of $113.5 million in 2024.
  • Per our database at Business Quant, Corcept Therapeutics' Shares Outstanding (Diluted Average) dropped by 11.28% in 2022 and then grew by 9.01% in 2025.
  • Corcept Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $126.0 million in 2021, then declined by 7.94% to $116.0 million in 2022, then declined by 3.64% to $111.7 million in 2023, then increased by 1.56% to $113.5 million in 2024, then grew by 5.50% to $120.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $120.0 million for Q3 2025, versus $120.5 million for Q2 2025 and $119.8 million for Q1 2025.